Advertisement
Canada markets open in 8 hours 9 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7326
    +0.0003 (+0.03%)
     

  • CRUDE OIL

    83.89
    +0.32 (+0.38%)
     

  • Bitcoin CAD

    87,689.13
    +121.02 (+0.14%)
     

  • CMC Crypto 200

    1,384.46
    +1.89 (+0.14%)
     

  • GOLD FUTURES

    2,347.80
    +5.30 (+0.23%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,760.00
    +192.50 (+1.10%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    38,032.85
    +404.37 (+1.07%)
     

  • CAD/EUR

    0.6829
    +0.0008 (+0.12%)
     

Wall Street Fundamentals Releases New In-Depth Stock Reports on ABIO, CHTP, NBS and SPPI

ACCESSWIRE

The Biotech Industry’s recent slide continued Friday as investors continued to shift their portfolios towards safer assets as we enter earnings season. On Friday, the iShares NASDAQ Biotechnology Index ETF (NASDAQ:IBB - News) declined 2.90 percent, down 15.44 percent in the past month, while the SPDR S&P Biotech ETF (NYSEARCA:XBI - News) fell 4.0 percent, down 20.95 over the same period. "There’s still a continual rotation out of the high-flying momentum stocks of 2013 into more value-driven opportunities," said Stifel Nicolaus portfolio manager Chad Morganlander. "This will continue in the coming weeks as investors look for consistency in earnings. You have concerns about high valuations and flat revenue growth, which is a perfect cocktail for a sector rotation out of growth and into value."

Arca Biopharma Inc. (NASDAQ:ABIO - News) shares traded in the range of $1.70 to $1.82 Friday before settling to close at $1.72, a decrease of 6.01 percent. The stock appears to be facing some resistance at the $1.76 and $1.80 levels with some support at $1.69 and $1.61. Shares of Arca Biopharma have fallen approximately 18.0 percent in the past month.

More information on Arca Biopharma and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ABIO

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP - News) shares traded in the range of $4.86 to $5.30 Friday before settling to close at $4.92, a decrease of 5.75 percent. The stock appears to be facing some resistance at the $5.39 and $5.77 levels with some support at $4.49 and $4.30. Shares of Chelsea Therapeutics have fallen approximately 17.0 percent in the past month.

ADVERTISEMENT

More information on Chelsea Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CHTP

NeoStem Inc. (NASDAQ:NBS - News) shares traded in the range of $6.30 to $6.76 Friday before settling to close at $6.40, a decrease of 5.88 percent. The stock appears to be facing some resistance at the $6.50 and $6.83 levels with some support at $6.13 and $6.05. Shares of NeoStem have fallen approximately 10.0 percent in the past month.

More information on NeoStem and access to the free equity report can be found at:
www.WallStreetFundamentals.com/NBS

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI - News) shares traded in the range of $6.79 to $7.30 Friday before settling to close at $6.79, a decrease of 5.17 percent. The stock appears to be facing some resistance at the $7.45, $7.71 and $7.97 levels. Shares of Spectrum Pharmaceuticals have fallen approximately 15.0 percent in the past month.

More information on Spectrum Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/SPPI

Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.

Activate your always free membership by signing up at www.WallStreetFundamentals.com today.

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com